Ann: MDR expects 1H FY23 revenue to be up 50-60% on 1H FY22, page-2

Back of an envelope calcs:
- ANZ revenues (with guidelink) of ~9.5m with a margin of 80% gives ~7.5m gross profit
- US revenues of 48.5m (58-9.5) with a margin of 40% gives ~19m Gross profit

There costs were running at ~27m in 2H22 so unless they have spent more on development/other costs to get these programs going, we could be looking at a flat PBT (and EBITDA positive).

I guess it might have been too much of a risk to highlight with this announcement, but the question is what can they do in 2H to revert back to another 7-10m loss (those margins in the US need to improve, and the revenues per pharmacy have to go up because tapping shareholders for money every so often should not be the case when you are annalising close to 100m in revenues).